Claims

1. A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole, wherein the crystalline form has a powder X-ray diffraction pattern comprises a peak at a diffraction angle (2θ) of 28.6 ± 0.2.

2. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 1, wherein the powder X-ray diffraction pattern further comprises peaks at diffraction angles (2θ) of 16.5 ± 0.2 and 26.7 ± 0.2.

3. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 1, wherein the powder X-ray diffraction pattern further comprises peaks at diffraction angles (2θ) of 15.4 ± 0.2 and 20.2 ± 0.2.

4. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 3, wherein the powder X-ray diffraction pattern further comprises a peak at a diffraction angle (2θ) of 29.0 ± 0.2.

5. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 4, wherein the powder X-ray diffraction pattern further comprises a peak at a diffraction angle (2θ) of 23.5 ± 0.2.

6. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of any one of claims 1 to 5, wherein the crystalline form has a solid state NMR spectrum comprising 13C chemical shifts (ppm) at 120.8 ± 0.2 and 127.7 ± 0.2.

7. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 6, wherein the solid state NMR spectrum further comprises 13C chemical shifts (ppm) at 139.6 ± 0.2.

8. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 6, wherein the solid state NMR spectrum further comprises 13C chemical shifts (ppm) at 144.7 ± 0.2.

9. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of any one of claims 1 to 8, wherein the crystalline form has a Raman spectrum comprising a Raman shift peak (cm-1) at 1292 ± 2.

10. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 9, wherein the crystalline form has a Raman spectrum further comprising Raman shift peaks (cm-1) at 994 ± 2, 1273 ± 2 and 1615 ± 2.

11. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 3, wherein the Raman spectrum further comprises Raman shift peaks (cm-1) at 287 ± 2 and 869 ± 2.

12. The crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole of claim 11, wherein the Raman spectrum further comprises a Raman shift peak (cm-1) at 213 ± 2.

13. The crystalline form of any one of claims 1 to 12, wherein the form is non-hygroscopic and anhydrous.

14. A pharmaceutical composition comprising the crystalline form of any one of claims 1 to 13 in a therapeutically effective amount in admixture with at least one pharmaceutically acceptable excipient.

15. The crystalline form of any one of claims 1 to 13 or a pharmaceutical composition of claim 14 for use in the treatment of transthyretin amyloid disease in a mammal.

16. Use of the crystalline form of any one of claims 1 to 13 or a pharmaceutical composition of claim 14 for the manufacture of a medicament for the treatment of transthyretin amyloid disease in a mammal.